Switch theme
Sign up to access all valuation multiples
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
2000
164
LTM Revenue $255M
LTM EBITDA $58.8M
$628M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Basilea Pharmaceutica has a last 12-month revenue of $255M and a last 12-month EBITDA of $58.8M.
In the most recent fiscal year, Basilea Pharmaceutica achieved revenue of $252M and an EBITDA of $80.0M.
Basilea Pharmaceutica expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Basilea Pharmaceutica valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $190M | $252M | XXX | XXX | XXX |
| Gross Profit | $149M | $158M | XXX | XXX | XXX |
| Gross Margin | 78% | 63% | XXX | XXX | XXX |
| EBITDA | $28.0M | $80.0M | XXX | XXX | XXX |
| EBITDA Margin | 15% | 32% | XXX | XXX | XXX |
| Net Profit | $14.7M | $12.6M | XXX | XXX | XXX |
| Net Margin | 8% | 5% | XXX | XXX | XXX |
| Net Debt | $101M | $61.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 1, 2025, Basilea Pharmaceutica's stock price is CHF 44 (or $53).
Basilea Pharmaceutica has current market cap of CHF 530M (or $639M), and EV of CHF 521M (or $628M).
See Basilea Pharmaceutica trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $628M | $639M | XXX | XXX | XXX | XXX | $6.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 1, 2025, Basilea Pharmaceutica has market cap of $639M and EV of $628M.
Basilea Pharmaceutica's trades at 2.5x LTM EV/Revenue multiple, and 10.7x LTM EBITDA.
Analysts estimate Basilea Pharmaceutica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Basilea Pharmaceutica and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $628M | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | 7.9x | XXX | XXX | XXX |
| P/E | 6.8x | XXX | XXX | XXX |
| P/E/Growth | -0.6x | XXX | XXX | XXX |
| EV/FCF | 7.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBasilea Pharmaceutica's NTM/LTM revenue growth is 9%
Basilea Pharmaceutica's revenue per employee for the last fiscal year averaged $1.5M, while opex per employee averaged $0.8M for the same period.
Over next 12 months, Basilea Pharmaceutica's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Basilea Pharmaceutica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Basilea Pharmaceutica and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 32% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 185% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 41% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 15% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 37% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 52% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Basilea Pharmaceutica acquired XXX companies to date.
Last acquisition by Basilea Pharmaceutica was XXXXXXXX, XXXXX XXXXX XXXXXX . Basilea Pharmaceutica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Basilea Pharmaceutica founded? | Basilea Pharmaceutica was founded in 2000. |
| Where is Basilea Pharmaceutica headquartered? | Basilea Pharmaceutica is headquartered in Switzerland. |
| How many employees does Basilea Pharmaceutica have? | As of today, Basilea Pharmaceutica has 164 employees. |
| Is Basilea Pharmaceutica publicy listed? | Yes, Basilea Pharmaceutica is a public company listed on SWX. |
| What is the stock symbol of Basilea Pharmaceutica? | Basilea Pharmaceutica trades under BSLN ticker. |
| When did Basilea Pharmaceutica go public? | Basilea Pharmaceutica went public in 2004. |
| Who are competitors of Basilea Pharmaceutica? | Similar companies to Basilea Pharmaceutica include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Basilea Pharmaceutica? | Basilea Pharmaceutica's current market cap is $639M |
| What is the current revenue of Basilea Pharmaceutica? | Basilea Pharmaceutica's last 12-month revenue is $255M. |
| What is the current EBITDA of Basilea Pharmaceutica? | Basilea Pharmaceutica's last 12-month EBITDA is $58.8M. |
| What is the current EV/Revenue multiple of Basilea Pharmaceutica? | Current revenue multiple of Basilea Pharmaceutica is 2.5x. |
| What is the current EV/EBITDA multiple of Basilea Pharmaceutica? | Current EBITDA multiple of Basilea Pharmaceutica is 10.7x. |
| What is the current revenue growth of Basilea Pharmaceutica? | Basilea Pharmaceutica revenue growth between 2023 and 2024 was 32%. |
| Is Basilea Pharmaceutica profitable? | Yes, Basilea Pharmaceutica is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
